Related Experiment Video

Updated: May 8, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Revealing targeted therapeutic opportunities in triple-negative breast cancers: a new strategy

Graham M Poage1, Zachary C Hartman, Powel H Brown

  • 1Department of Clinical Cancer Prevention; The University of Texas MD Anderson Cancer Center; Houston, TX USA.

Cell Cycle (Georgetown, Tex.)
|August 23, 2013
PubMed
Abstract

No abstract available in PubMed .

Keywords:
EZH2JAK/STATLPAcytokine/chemokinetandem inhibitiontargeted therapytranscriptional profilingtriple-negative breast cancertumor stem cell

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Related Experiment Videos

Last Updated: May 8, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Articles linked to this work by shared authors, journal, and citation graph.

Reporter immunogenicity as a defined rejection antigen: a noninvasive platform for skin transplant immunobiology.

Frontiers in immunology·2026

Development of a STEAP1-Targeted Prostate Cancer Specific Antibody Drug Conjugate Platform with Immunostimulatory Properties.

Research square·2026

Enhanced efficacy of a next-generation EEEV self-replicating RNA platform for combination cancer immunotherapies.

Molecular therapy : the journal of the American Society of Gene Therapy·2026

Vector-directed immunity and boosting capacity of VRP-srRNA anti-tumor vaccines.

NPJ vaccines·2026

Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial.

Nature medicine·2026

Inhibition of GPX4 induces the death of p53-mutant triple-negative breast cancer cells.

Breast cancer research and treatment·2026

Meta-analysis of NPC2-mediated cholesterol transport in human cancers as a prognostic biomarker with therapeutic implications.

Cell cycle (Georgetown, Tex.)·2026

Citron Kinase, a mitotic kinase with increasing significance in cancer.

Cell cycle (Georgetown, Tex.)·2026

Regulatory roles of pyroptosis-associated lncRnas in breast cancer progression and immune microenvironment.

Cell cycle (Georgetown, Tex.)·2026

From dysbiosis to precision oncology: translational role of the microbiome in gastrointestinal cancer.

Cell cycle (Georgetown, Tex.)·2026

Upregulation of ITM2A by p53 activation modulates p53 function through physical interaction.

Cell cycle (Georgetown, Tex.)·2026

The hormetic landscape: from evolutionary origination to mechanistic pathways in therapeutics.

Cell cycle (Georgetown, Tex.)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us